Artificial intelligence in hematology
Clinical Snapshot
PICO Framework
| P — Population | Healthcare professionals and researchers in hematology |
| I — Intervention | Artificial intelligence and machine learning applications |
| C — Comparator | Traditional clinical decision-making and diagnostic approaches |
| O — Outcomes | Diagnostic accuracy, risk stratification, treatment response prediction, clinical implementation challenges |
Bottom Line
This comprehensive review highlights the significant potential of AI and machine learning to transform hematology practice through improved diagnostic accuracy, risk stratification, and personalized treatment approaches. The integration of diverse data sources including imaging, pathology, omics, and laboratory parameters presents opportunities for more precise clinical decision-making. However, the authors identify critical implementation barriers including data quality issues, equity concerns, infrastructure requirements, and lack of robust regulatory frameworks. While generative AI shows particular promise for enhancing diagnostic workflows and therapeutic development, the gap between potential and clinical reality remains substantial. For Australian hematologists, this review underscores the need for strategic planning around AI implementation, including consideration of TGA regulatory pathways and integration with existing clinical workflows. The emphasis on addressing bias and ensuring equitable access aligns with Australian healthcare values, but significant investment in infrastructure and training will be required to realize these benefits.
Key Findings
Effect Size: Not quantified - narrative review format
Primary Outcome: AI/ML show potential for enhancing diagnostic accuracy, risk stratification, and treatment prediction in hematology
Nnt Or Sensitivity: Few AI/ML tools fully implemented in clinical practice despite potential benefits
Clinical Application
Limited by data quality issues, infrastructure requirements, and regulatory frameworks Relevant to Australian hematology practice; implementation would require TGA approval for diagnostic tools and consideration of PBS funding for AI-enhanced diagnostics Hematologists, pathologists, laboratory medicine specialists, and healthcare administrators
Abstract
Artificial intelligence (AI) and its subdiscipline, machine learning (ML), have the potential to revolutionize health care, including hematology. The diagnosis and treatment of hematologic disorders depend on the integration of diverse data sources, such as imaging, pathology, omics, and laboratory parameters. The increasing volume and complexity of patient data have made clinical decision-making more challenging. AI/ML hold significant potential for enhancing diagnostic accuracy, risk stratification, and treatment response prediction through advanced modeling techniques. Generative AI, a recent advancement within the broader field of AI, is poised to have a profound impact on health care and hematology. Generative AI can enhance the development of novel therapeutic strategies, improve diagnostic workflows by generating high-fidelity images or pathology reports, and facilitate more personalized approaches to patient management. Its ability to augment clinical decision-making and streamline research represents a significant leap forward in the field. However, despite this potential, few AI/ML tools have been fully implemented in clinical practice due to challenges related to data quality, equity, advanced infrastructure, and the establishment of robust evaluation metrics. Despite its promise, AI implementation in hematology faces critical challenges, including bias, data quality issues, and a lack of regulatory frameworks and safety standards that keep pace with rapid technological advancements. In this review, we provide an overview of the current state of AI/ML in hematology as of 2025, identify existing gaps, and offer insights into future developments.
References
- 1.Nazha, A., Elemento, O., Ahuja, S., Lam, B., Miles, M., Shouval, R., McWeeney, S., Sirhan, S., Srisuwananukorn, A., & Haferlach, T. (2025). Artificial intelligence in hematology. Blood. https://doi.org/10.1182/blood.2025029876
Related Research
Blood advances
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis
27 May 2026
European journal of pediatrics
Safety and efficacy of liposomal iron for iron deficiency anemia in pediatric population: A systematic review and meta-analysis of randomized controlled trials
26 May 2026
The Cochrane database of systematic reviews
Early erythropoiesis-stimulating agents in preterm or low-birthweight infants
25 May 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service